Xerecept

Xerecept Uses, Dosage, Side Effects, Food Interaction and all others data.

Corticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.

Xerecept
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Xerecept
Availability	Prescription only
Generic	Corticorelin
Corticorelin Other Names	Corticoliberin human, Corticorelin, Corticorelin (human), Corticotropin releasing hormone human, Corticotropin-releasing factor, Corticotropin-releasing hormone, hCRF, Human corticoliberin, Human corticotropin-releasing factor
Related Drugs	dexamethasone, Decadron, cyproheptadine, mifepristone
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Xerecept is a synthetic corticotropin-releasing factor analog used to diagnose causes of excessive adrenocorticotropic hormone (ACTH) production.

Investigated for use/treatment in brain cancer and neurologic disorders.

How Xerecept works

Corticotropin-releasing factor is produced by neuroendocrine cells in the paraventricular nucleus of the hypothalamus and is released from neurosecretory terminals of these neurons into the primary capillary plexus of the hypothalamo-hypophyseal portal system. The portal system carries the Corticotropin-releasing hormone(CRH) to the anterior lobe of the pituitary where it stimulates the secretion of corticotropin (ACTH) and other biologically active substances.

Xerecept Hypertension interaction

[Major] Adrenocorticotropic agents may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure.

Therapy with these agents, particularly if intended for longer than brief periods, should be administered cautiously in patients with preexisting fluid retention or conditions that may be aggravated by these effects.

Dietary sodium restriction and potassium supplementation may be advisable.

The manufacturers consider the use of adrenocorticotropic agents to be contraindicated in patients with congestive heart failure or uncontrolled hypertension.